Head-to-head comparative trials for first line ART since 2006

VEMAN Study: LPV/r + MVC vs LPV/r + TDF/FTC
Original article : Clin Microbiol Infect. 2015 May;21(5):510 - S Nozza
Last update : 18/07/2016

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

  • Among naive patients with an R5 virus, treatment with MVC and LPV/r was shown to provide a virological response compared to a triple therapy and a greater immunological benefit
  • Limitations
    • Small sample size
    • Unpowered to establish non-inferiority
    • AEs self-reported, open-label unblinded design



  • Primary endpoint: 12-week change of HIV-1 RNA from baseline (ITT analysis), difference between groups assessed by the Wilcoxon signed rank test, no formal statistical hypothesis
  • Viral rebound: 2 consecutive HIV RNA > 50 copies/mL

Baseline characteristics (mean), and disposition

Virologic efficacy and immunologic response


Back to Table of Contents

Copyright AEI 2018 | Links | Contact | Editorial Office | Faculty and Disclosure | Terms of use aei